Safety of Varenicline for Smoking Cessation in Psychiatric and Addicts Patients

Substance Use and Misuse

Volumn 51, Issue 5, 2016, Pages 649-657

  Raich, Antonia ^a,b,c   Ballbe, Montse ^b,d   Nieva, Gemma ^e   Cano, Margarita ^f   Fernandez, Teresa ^f   Bruguera, Eugeni ^e   Fernandez, Esteve ^b,c  

^a Althaia   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL DE MATARÓ   (Spain)

Author keywords

alcohol dependence; methadone treatment; psychotic disorder; Smoking cessation; varenicline

Indexed keywords

NICOTINE GUM; VARENICLINE;

ADULT; CLINICAL TRIAL; COUNSELING; DRUG DEPENDENCE; DRUG THERAPY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; SMOKING; SMOKING CESSATION;

ADULT; COUNSELING; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MIDDLE AGED; PROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84964033651     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2015.1133646     Document Type: Article

References (41)

1. Addington, J., El-Guebaly, N., Campbell, W., Hodgins, D. C., Addington, D. (1998). Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry, 155, 974-976.
2. Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Jr,. Reeves, K. R. (2008). Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax, 63 (8), 717-724. doi: 10.1136/thx.2007.090647
3. Cahill, K., Stead, L., Lancaster, T. (2009). A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Safety, 32 (2), 119-135. doi: 10.2165/00002018-200932020-00005
4. Cahill, K., Stead, L. F., Lancaster, T. (2011). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews (Online), (2)(2), CD006103. doi: 10.1002/14651858.CD006103.pub5
5. Chou, K. R., Chen, R., Lee, J. F., Ku, C. H., Lu, R. B. (2004). The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. International Journal of Nursing Studies, 41 (3), 321-330.
6. Colton, C. W., Manderscheid, R. W. (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease, 3 (2), A42.
7. Crunelle, C. L., Miller, M. L., Booij, J., van den Brink, W. (2010). The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review. European Neuropsychopharmacology, 20 (2), 69-79. doi: 10.1016/j.euroneuro.2009.11.001
8. Etter, J. F. (2006). Cytisine for smoking cessation: A literature review and a meta-analysis. Archives of Internal Medicine, 166 (15), 1553-1559. doi: 10.1001/archinte.166.15.1553
9. European Medicines Agency. (2006). Scientific discussion (Var-enicline). Retrieved from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Scientific-Discussion/human/000699/WC500025254.pdf
10. Evins, A. E., Cather, C., Deckersbach, T., Freudenreich, O., Culhane, M. A., Olm-Shipman, C. M., Rigotti, N. A. (2005). A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical Psychopharmacology, 25 (3), 218-225.
11. Evins, A. E., Goff, D. C. (2008). Varenicline treatment for smokers with schizophrenia: A case series. Journal of Clinical Psychiatry, 69, 1016.
12. Garrison, G. D., Dugan, S. E. (2009). Varenicline: A first-line treatment option for smoking cessation. Clinical Therapeutics, 31 (3), 463-491. doi: 10.1016/j.clinthera.2009.03.021
13. George, T. P., Vessicchio, J. C., Sacco, K. A., Weinberger, A. H., Dudas, M. M., Allen, T. M.,. &, Jatlow, P. I. (2008). A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biological Psychiatry, 63 (11), 1092-1096.
14. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B.,. Varenicline Phase 3 Study Group. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA, 296 (1), 47-55. doi: 10.1001/jama.296.1.47
15. Grant, K. M., Kelley, S. S., Smith, L. M., Agrawal, S., Meyer, J. R., Romberger, D. J. (2007). Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol, 41 (5), 381-391.
16. Gunnell, D., Irvine, D., Wise, L., Davies, C., Martin, R. M. (2009). Varenicline and suicidal behaviour: A cohort study based on data from the general practice research database. BMJ (Clinical Research Ed.), 339, b3805. doi: 10.1136/bmj.b3805
17. Hitsman, B., Moss, T. G., Montoya, I. D., George, T. P. (2009). Treatment of tobacco dependence in mental health and addictive disorders. Canadian Journal of Psychiatry, 54 (6), 368-378.
18. Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E.,. Reeves, K. R. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA, 296 (1), 56-63. doi: 10.1001/jama.296.1.56
19. Kalman, D., Morissette, S. B., George, T. P. (2005). Co-morbidity of smoking in patients with psychiatric and substance use disorders. The American Journal on Addictions, 14 (2), 106-123. doi: 10.1080/10550490590924728
20. Kessler, R. C., Borges, G., Sampson, N., Miller, M., Nock, M. K. (2009). The association between smoking and subsequent suicide-related outcomes in the national comorbidity survey panel sample. Molecular Psychiatry, 14 (12), 1132-1142. doi: 10.1038/mp.2008.78
21. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., Bor, D. H. (2000). Smoking and mental illness: A population-based prevalence study. JAMA, 284 (20), 2606-2610.
22. Lopez-Ibor, J., Valdés, M. (2002). DSM-IV-TR breviario: criterios diagnosticos Masson. Barcelona, Spain: Masson.
23. McClure, J. B., Swan, G. E., Jack, L., Catz, S. L., Zbikowski, S. M., McAfee, T. A.,. Javitz, H. (2009). Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. Journal of General Internal Medicine, 24 (5), 563-569. doi: 10.1007/s11606-009-0926-8
24. Middleton, E. T., Morice, A. H. (2000). Breath carbon monoxide as an indication of smoking habit. Chest, 117 (3), 758-763.
25. Nahvi, S., Wu, B., Richter, K. P., Bernstein, S. L., Arnsten, J. H. (2013). Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness. Drug and Alcohol Dependence, 132 (1), 47-52.
26. Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T., Reeves, K. R. (2007). Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics, 29 (6), 1040-1056. doi: 10.1016/j.clinthera.2007.06.012
27. Nides, M., Oncken, C., Gonzales, D., Rennard, S., Watsky, E. J., Anziano, R.,. Varenicline Phase 3 Study Group. (2006). Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine, 166 (15), 1561-1568. doi: 10.1001/archinte.166.15.1561
28. Nock, M. K., Borges, G., Bromet, E. J., Alonso, J., Angermeyer, M., Beautrais, A.,. Williams, D. (2008). Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. The British Journal of Psychiatry, 192 (2), 98-105. doi: 10.1192/bjp.bp.107.040113
29. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C. B.,. Varenicline Phase 3 Study Group. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166 (15), 1571-1577. doi: 10.1001/archinte.166.15.1571
30. Philip, N. S., Carpenter, L. L., Tyrka, A. R., Whiteley, L. B., Price, L. H. (2009). Varenicline augmentation in depressed smokers: An 8-week, open-label study. The Journal of Clinical Psychiatry, 70 (7), 1026-1031.
31. Purvis, T. L., Mambourg, S. E., Balvanz, T. M., Magallon, H. E., Pham, R. H. (2009). Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. The Annals of Pharmacotherapy, 43 (5), 862-867. doi: 10.1345/aph.1L661
32. Reus, V. I., Obach, R. S., Coe, J. W., Faessel, H., Rollema, H., Watsky, E., & Reeves, K. R. (2007). Varenicline: New treatment with efficacy in smoking cessation. Drugs of Today, 43 (2), 65-75. doi: 10.1358/dot.2007.43.2.1069956
33. Stapleton, J. A., Watson, L., Spirling, L. I., Smith, R., Milbrandt, A., Ratcliffe, M., & Sutherland, G. (2008). Varenicline in the routine treatment of tobacco dependence: A pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction, 103 (1), 146-154. doi: 10.1111/j.1360-0443.2007.02083.x
34. Stein, M. D., Weinstock, M. C., Herman, D. S., Anderson, B. J., Anthony, J. L., Niaura, R. (2006). A smoking cessation intervention for the methadone-maintained. Addiction, 101 (4), 599-607.
35. Tobacco Use and Dependence Guideline Panel. (2009). Treating tobacco use and dependence: 2008 update (Quick reference guide for clinicians). Rockville, MD: U.S. Department of Health and Human Services.
36. Tonstad, S., Davies, S., Flammer, M., Russ, C., Hughes, J. (2010). Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: A pooled analysis. Drug Safety, 33 (4), 289-301. doi: 10.2165/11319180-000000000-00000
37. Tonstad, S., Tonnesen, P., Hajek, P., Williams, K. E., Billing, C. B., Reeves, K. R., & Varenicline Phase 3 Study Group. (2006). Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA, 296 (1), 64-71. doi: 10.1001/jama.296.1.64
38. US Food and Drug Administration. (n.d.). What is a serious adverse event? Retrieved from http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm
39. US Food and Drug Administration Centre for Drug Evaluation and Research. (2007). Early communication about an ongoin safety review: Varenicline. Retrieved from http://www.fda.gov/medwatch/safety/2007/safety07.htm#chantix
40. Williams, K. E., Reeves, K. R., Billing, C. B., Jr, Pennington, A. M., Gong, J. (2007). A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion, 23 (4), 793-801. doi: 10.1185/030079907'182185
41. Ziedonis, D. M., D'Avanzo, K. (1998). Schizophrenia and substance abuse. In H. R. Dranzler & B. J. Rounsaville (Eds.), Dual diagnosis and treatment: Substance abuse and comorbid medical and psychiatric disorders (pp. 427-459). New York, NY: Marcel Dekker.